由 Gus Iversen
, Editor in Chief | December 24, 2020
ENDRA Life Sciences, the developer of Thermo Acoustic Enhanced Ultrasound (TAEUS), has renewed its collaboration agreement with GE Healthcare, extending the agreement's previous 12-month term by an additional two years.
TAEUS visualizes tissue in a way that is comparable to MR, according to ENDRA, but at a small fraction of the cost and at the point of care. The technology is designed to work in concert with the over one million ultrasound systems in use globally today.
Through the collaboration, GE will continue to support ENDRA's efforts to commercialize a fatty liver diagnostic application by facilitating introductions to its clinical ultrasound customers worldwide. In return, ENDRA will afford GE certain rights of first offer with respect to manufacturing and licensing the application.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
"Over the past 60 days ENDRA has deployed its first clinical systems to Rocky Vista University and the University of Pittsburgh Medical Center, signed a clinical evaluation agreement with a second European site at CHU-Angers France, signed an exclusive three-year agreement with a Vietnamese distributor for more than 40 TAEUS systems, and received its seventh Chinese patent for TAEUS," said Francois Michelon, CEO of ENDRA, in a statement. "We have remarkable momentum as we cross the 2020 finish line and enter 2021."
TAEUS, which is pending FDA 510(k) approval, is focused on the measurement of fat in the liver as a means to assess and monitor non-alcoholic fatty liver disease (NAFLD) and inflammation (non-alcoholic steatohepatitis – NASH), chronic liver conditions that affect over one billion people globally. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
"ENDRA's technology has the potential to bring significant new capabilities to ultrasound and address unmet clinical needs in point-of-care NAFLD/NASH assessment and monitoring, which aligns with GE Healthcare's mission to increase access to high-quality, cost-effective healthcare," said Brian McEathron, GE Healthcare's vice president and general manager for general imaging ultrasound. "We're excited to help bring the TAEUS fatty liver product to market and help improve patient outcomes."
ENDRA and GE Healthcare have been partnering since 2016. The announcement extends that partnership to December 16, 2023.